Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with T2D.

Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Presentation Title: Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass and Physical Function in Older Patients Receiving Semaglutide for Weight Loss Date: April 30, 2025 Start time: 12:30 ...

Increased awareness and knowledge of GLP-1/GIP receptor agonists among women, with insights into public perspectives on ...

There were 396,963 eligible patients with T2D, of whom 33,858 were included in the GLP-1 RA versus the other glucose-lowering drug (GLD) cohort; 34,185 in the SGLT2i versus the other GLD cohort ...

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022. (HealthDay News) — Among U.S. adults without diabetes, the use of glucagon-like ...